Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
A Phase 1b Study of Ficlatuzumab, Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Intermediate or High Risk, Previously Untreated, Locally Advanced Head and Neck Squamous Cell Carcinoma With Biomarker Correlatives
Sponsor: AVEO Pharmaceuticals, Inc.
Terminated
the investigator left the institution
Other terminated trials from AVEO Pharmaceuticals, Inc.
- Hepatocellular Carcinoma · Phase PHASE1/PHASE2 · Apr 2023
- Acute Myeloid Leukemia · Phase PHASE1 · Dec 2019
- Non-small Cell Lung Cancer · Phase PHASE2 · Jan 2017
- Fallopian Tube Cancer · Phase PHASE2 · Jan 2016
- Solid Tumors · Phase NA · Oct 2015
More terminations from AVEO Pharmaceuticals, Inc.
A PHASE1 clinical study on Carcinoma, Squamous Cell of Head and Neck, this trial is terminated or withdrawn. The trial is conducted by AVEO Pharmaceuticals, Inc. and has accumulated 6 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Sep 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AVEO Pharmaceuticals, Inc.
- Julie E. Bauman, MD, MPH
For direct contact, visit the study record on ClinicalTrials.gov .